Publications by authors named "Anna Maciag"

Myofascial pain represents the largest subgroup of temporomandibular disorders (TMD) that account for a common cause of non-dental orofacial pain. The management of TMD is complex due to the chronic nature of the condition, alongside acute episodes presenting to the clinician. A fundamental part of TMD management is consideration of the biopsychosocial element in its aetiology.

View Article and Find Full Text PDF

Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. This approach provides no direct target coverage of the active protein. Expectedly, adaptive resistance to KRASG12C (OFF)-only inhibitors is observed in association with increased expression and activity of KRASG12C(ON).

View Article and Find Full Text PDF

We present a novel method to determine engagement and specificity of KRAS4B-targeting compounds in vitro. By employing top-down mass spectrometry (MS), which analyzes intact and modified protein molecules (proteoforms), we can directly visualize and confidently characterize each KRAS4B species within compound-treated samples. Moreover, by employing targeted MS2 fragmentation, we can precisely localize each compound molecule to a specific residue on a given KRAS4B proteoform.

View Article and Find Full Text PDF

As temporomandibular disorders (TMDs) become ever more prevalent in both primary and secondary care settings, successful management is increasingly challenging in both sectors. The authors aim to explore the dilemma of TMD management as the patient journeys through from primary to secondary care and offer educational tools to support practitioners in managing this complex patient cohort, as well as outlining alternative solutions for the delivery of TMD management strategies.

View Article and Find Full Text PDF

Beyond their activity in hemostasis and thrombosis, recent advances attribute platelets a pro-youthful role capable to attenuate immune senescence and age-related neuroinflammation. Previous studies from our group associated a polymorphic haplotype variant in the BPIFB4 gene (LAV-BPIFB4) with exceptional longevity. Transfer of the LAV-BPIFB4 in preclinical models has proved strategic to cope with frailty conditions, aging-related events, e.

View Article and Find Full Text PDF

The programmed cell death pathways of apoptosis are important in mammalian cellular protection from infections. The activation of these pathways depends on the presence of membrane receptors that bind bacterial components to activate the transduction mechanism. In addition to bacteria, these mechanisms can be activated by outer membrane vesicles (OMVs).

View Article and Find Full Text PDF

Prior analysis of intact and modified protein forms (proteoforms) of KRAS4B isolated from cell lines and tumor samples by top-down mass spectrometry revealed the presence of novel posttranslational modifications (PTMs) and potential evidence of context-specific KRAS4B modifications. However, low endogenous proteoform signal resulted in ineffective characterization, making it difficult to visualize less abundant PTMs or perform follow-up PTM validation using standard proteomic workflows. The NCI RAS Initiative has developed a model system, whereby KRAS4B bearing an N-terminal FLAG tag can be stably expressed within a panel of cancer cell lines.

View Article and Find Full Text PDF

With recent advances proving that effective inhibition of KRAS is possible, there have been significant efforts made to develop inhibitors of specific mutant alleles. Here we describe a detailed protocol that employs homogeneous time-resolved fluorescence (HTRF) to identify compounds acting on KRAS signaling in malignant cell lines. This method allows for high-throughput, cell-based screens of large compound libraries for the development of RAS-targeted therapeutics.

View Article and Find Full Text PDF

MALDI-TOF mass spectrometry enables high-throughput screening of covalent fragment libraries and SAR compound progressions of selective KRAS G12C inhibitors. Using the MALDI-TOF platform instead of the more traditional ESI-MS TOF/orbitrap instrumentation can radically shorten sample acquisition time, allowing up to 384 samples to be screened in 30 min. The typical throughput for a covalent library screen is 1152 samples per 8 h, including processing, calculation, and reporting steps.

View Article and Find Full Text PDF

Development of new targeted inhibitors for oncogenic KRAS mutants may benefit from insight into how a given mutation influences the accessibility of protein residues and how compounds interact with mutant or wild-type KRAS proteins. Targeted proteomic analysis, a key validation step in the KRAS inhibitor development process, typically involves both intact mass- and peptide-based methods to confirm compound localization or quantify binding. However, these methods may not always provide a clear picture of the compound binding affinity for KRAS, how specific the compound is to the target KRAS residue, and how experimental conditions may impact these factors.

View Article and Find Full Text PDF
Article Synopsis
  • Oncogenic KRAS mutants show different biochemical behaviors due to their unique conformations; they exist in two primary states, active (state 2) and inactive (state 1), which are influenced by how they bind to molecules like GTP and GppNHp.
  • Research using P NMR has revealed that KRAS bound to GTP primarily adopts the active state (over 90% in state 2), while GppNHp-bound KRAS shows a significant population in the inactive state 1, a condition likely not seen in living cells.
  • A new small-molecule inhibitor, BBO-8956, has been developed that targets KRAS G12C and disrupts the state 1-state
View Article and Find Full Text PDF
Article Synopsis
  • Long-living individuals tend to avoid age-related heart issues until their final years, possibly due to a specific gene variant (LAV-BPIFB4) linked to prolonged life.
  • Studies on mice show that the LAV-BPIFB4 gene can help improve heart function and blood vessel health in conditions like atherosclerosis and diabetes.
  • In humans, lower levels of BPIFB4 are associated with more severe coronary artery disease, and adding LAV-BPIFB4 shows promise as a potential treatment for heart conditions.
View Article and Find Full Text PDF

Aims: The ageing heart naturally incurs a progressive decline in function and perfusion that available treatments cannot halt. However, some exceptional individuals maintain good health until the very late stage of their life due to favourable gene-environment interaction. We have previously shown that carriers of a longevity-associated variant (LAV) of the BPIFB4 gene enjoy prolonged health spans and lesser cardiovascular complications.

View Article and Find Full Text PDF

Huntington's disease (HD) is caused by the production of mutant Huntingtin (mHTT), characterized by long polyglutamine repeats with toxic effects. There are currently no clinically validated therapeutic agents that slow or halt HD progression, resulting in a significant clinical unmet need. The striatum-derived STHdh cell line, generated from mHTT knock-in mouse embryos (STHdh), represents a useful model to study mechanisms behind pathogenesis of HD and to investigate potential new therapeutic targets.

View Article and Find Full Text PDF

In the ongoing global COVID-19 pandemic, male sex is a risk factor for severe disease and death, and the reasons for these clinical discrepancies are largely unknown. The aim of this work is to study the influence of sex on the course of infection and the differences in prognostic markers between genders in COVID-19 patients. Our cohort consisted of 64 adult patients ( = 34 men and = 30 women) with PCR-proven SARS-CoV-2 infection.

View Article and Find Full Text PDF

RAS proteins cycling between the active-form (GTP-bound) and inactive-form (GDP-bound) play a key role in cell signaling pathways that control cell survival, proliferation, and differentiation. Mutations at codon 12, 13, and 61 in RAS are known to attenuate its GTPase activity favoring the RAS active state and constitutively active downstream signaling. This hyperactivation accounts for various malignancies including pancreatic, lung, and colorectal cancers.

View Article and Find Full Text PDF

Circulating levels of soluble receptor for advanced glycation end products (sRAGE) and advanced glycation end products (AGEs) correlate with aging/cardiovascular risk, which is delayed in long-living individuals (LLIs). AGEs/sRAGE isoforms (cleaved RAGE [cRAGE] and secretory RAGE [esRAGE]) ratio is a valuable marker for disease risk. We evaluated circulating sRAGE isoforms, and AGEs in LLIs (n = 95; 90-105 years) and controls (n = 94; 11-89 years).

View Article and Find Full Text PDF

Bitter taste receptors (TAS2R) are involved in a variety of non-tasting physiological processes, including immune-inflammatory ones. Therefore, their genetic variations might influence various traits. In particular, in different populations of South Italy (Calabria, Cilento, and Sardinia), polymorphisms of TAS2R16 and TAS238 have been analysed in association with longevity with inconsistent results.

View Article and Find Full Text PDF

The longevity-associated variant (LAV) of the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) has been found significantly enriched in long-living individuals. Neuroinflammation is a key player in Huntington's disease (HD), a neurodegenerative disorder caused by neural death due to expanded CAG repeats encoding a long polyglutamine tract in the huntingtin protein (Htt). Herein, we showed that striatal-derived cell lines with expanded Htt (STHdh Q) expressed and secreted lower levels of BPIFB4, when compared with Htt expressing cells (STHdh Q), which correlated with a defective stress response to proteasome inhibition.

View Article and Find Full Text PDF

Aims: Homozygosity for a four-missense single-nucleotide polymorphism haplotype of the human BPIFB4 gene is enriched in long-living individuals. Delivery of this longevity-associated variant (LAV) improved revascularisation and reduced endothelial dysfunction and atherosclerosis in mice through a mechanism involving the stromal cell-derived factor-1 (SDF-1). Here, we investigated if delivery of the LAV-BPIFB4 gene may attenuate the progression of diabetic cardiomyopathy.

View Article and Find Full Text PDF

Background: There is an increasing concern about age-related frailty because of the growing number of elderly people in the general population. The Longevity-Associated Variant (LAV) of the human gene was found to correct endothelial dysfunction, one of the mechanisms underlying frailty, in aging mice whereas the variant induced opposite effects. Thus, we newly hypothesize that, besides being associated with life expectancy, polymorphisms can predict frailty.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the effects of a gene therapy using the longevity-associated variant (LAV)-BPIFB4 on atherosclerosis in mice designed to mimic human cardiovascular conditions.
  • - LAV-BPIFB4 improved endothelial function in atherosclerosis-affected mice, influenced immune cell behavior by shifting macrophages to an anti-inflammatory state, and altered levels of important cytokines.
  • - Findings suggest that LAV-BPIFB4 therapy can mitigate atherosclerosis progression, presenting new potential treatments for cardiovascular diseases by reprogramming immune responses through the CXCR4 pathway.
View Article and Find Full Text PDF

One of the basis of exceptional longevity is the maintaining of the balance between inflammatory and anti-inflammatory networks. The monocyte-macrophages activation plays a major role in tuning the immune responses, by oscillating between patrolling-protective to inflammatory status. Longevity-associated variant (LAV) of bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) activates calcium, PKC-alpha, and eNOS, rescuing endothelial dysfunction in aged mice and inducing revascularization.

View Article and Find Full Text PDF